The GLP-1 Revolution: How Obesity Drugs Are Reshaping Healthcare IB

Introduction

GLP-1 receptor agonists have grown from a niche diabetes treatment into the most commercially significant drug class of the last two decades. Tirzepatide (Eli Lilly's Mounjaro and Zepbound) generated $36.5 billion in 2025, making it the world's best-selling drug molecule, and semaglutide (Novo Nordisk's Ozempic, Wegovy and Rybelsus) added roughly $34.5 billion, together passing $70 billion. The market has also changed shape, from a supply-constrained duopoly of weekly injections to a price-cut, pill-led market with generic semaglutide already sold outside the US. For healthcare bankers, GLP-1 is a cross-cutting force: it generates M&A, reshaped manufacturing economics and disrupts adjacent markets, creating winners and losers across the ecosystem.

Two companies still control most of the market, but the order has flipped. Novo Nordisk built the category; its semaglutide brands sold about DKK 228 billion in 2025, the $34.5 billion above at the year's average exchange rate. Eli Lilly now leads: in Q2 2026 alone, Lilly reported Mounjaro and Zepbound sales of $9.9 billion and $4.9 billion, and it raised its full-year 2026 revenue guidance to $85-87 billion, from $65.2 billion in 2025. Novo expects 2026 sales between flat and 6% lower, for reasons covered in the price reset below.

GLP-1 Receptor Agonist

A class of drugs that mimic the glucagon-like peptide-1 (GLP-1) hormone, which stimulates insulin secretion, slows gastric emptying and acts on brain appetite centers to reduce food intake. Originally developed for type 2 diabetes, GLP-1 agonists produced 15-25% body weight reduction in obesity trials, making them blockbuster weight-loss therapies. Next-generation agents combine GLP-1 with other incretin targets (GIP, glucagon, amylin) to enhance efficacy.

Novo and Lilly compete on efficacy (weight loss percentage), tolerability (GI side effects), convenience (dosing frequency, and now pill versus injection) and, increasingly, net price. Tirzepatide, a dual GIP/GLP-1 agonist, has shown modestly superior weight loss in head-to-head positioning, while semaglutide has a larger body of outcomes data, including the landmark SELECT cardiovascular outcomes trial that demonstrated a 20% reduction in major adverse cardiovascular events (MACE).

Every major pharma company and dozens of biotechs are chasing the opportunity with over 50 GLP-1 and incretin candidates in clinical development, and the first big format shift, from injections to pills, has already reached the market.

The two obesity pills arrived four months apart. The FDA approved the Wegovy pill (oral semaglutide 25 mg) on December 22, 2025, and Novo launched it in the US on January 5, 2026, passing 5 million prescriptions by mid-2026. Lilly's Foundayo (orforglipron) won approval on April 1, 2026 after a 50-day FDA review and booked $98 million in its first quarter. Both start at $149 a month self-pay, so pills are entering as the cheaper option, not a premium one.

Oral GLP-1

A GLP-1 drug taken as a daily pill instead of an injection. Peptide versions such as oral semaglutide (Rybelsus, the Wegovy pill) need absorption-enhancing technology, a much higher dose and an empty stomach, because the GI tract degrades peptides. Small molecules such as orforglipron (Foundayo) avoid those limits and are easier to manufacture at scale. The commercial thesis is that pills remove the injection barrier that keeps many eligible patients off therapy.

The pipeline intensity is directly driving M&A. Pfizer's $10 billion acquisition of Metsera, won from Novo in a bidding war in November 2025, bought long-acting injectable GLP-1 technology after Pfizer dropped its own oral candidate (danuglipron). Novo Nordisk's $5.2 billion acquisition of Akero (December 2025) added efruxifermin, a non-GLP-1 drug for MASH, a liver disease closely linked to metabolic dysfunction. Roche acquired Carmot Therapeutics for $2.7 billion (plus $400 million in milestones) to enter the GLP-1 space.

GLP-1 cash is also funding deals far beyond obesity. Lilly's Q2 2026 10-Q records 2026 acquisitions of Ventyx (inflammation, about $1.2 billion), Centessa (sleep-wake disorders, about $6.6 billion) and Kelonia (in vivo CAR-T, about $4.9 billion), including contingent payments, plus Orna, Ajax and three infectious disease companies. The leading incretin franchise is recycling its cash into diversification before its own patents expire, while Lilly plans to file its next obesity asset, the triple agonist retatrutide, with the FDA in the first quarter of 2027.

The second shift is price. In November 2025, Lilly and Novo signed most-favored-nation (MFN) agreements with the White House, trading MFN prices for Medicaid, Medicare obesity coverage and lower cash prices via TrumpRx and their own direct-to-patient channels for a three-year tariff reprieve (see MFN pricing, TrumpRx and pharma tariffs). Cash prices now run from about $149 a month for starter pill doses to about $350 for injectables.

The Medicare GLP-1 Bridge, a CMS pilot scheduled to run through 2027, has covered GLP-1s for weight loss in eligible Part D beneficiaries since July 1, 2026 at a $50 monthly copay, with manufacturers paid a net $245 a month. That opens coverage to an estimated 3.8 million beneficiaries at a far lower price per patient: more volume, less revenue per script.

Lilly is not immune: its worldwide realized prices fell 13% in Q2 2026, mostly on Mounjaro's addition to China's national reimbursement list, though volume more than offset it. The reset has also cut market forecasts. Analysts once expected obesity drugs to reach $150 billion within a decade; a Reuters analysis in February 2026 found 2030 forecasts about 30% lower, near $100 billion.

Generics: Semaglutide Reaches Its Own Patent Cliff

Outside the US, semaglutide's compound patent has started to expire. Natco, Sun Pharma, Zydus and other Indian manufacturers launched generics after it lapsed there in March 2026, and Dr. Reddy's won the first Health Canada approval for generic semaglutide on April 28, 2026, the first such approval in a G7 country. Several generic applications are under review in China, and Novo says loss of exclusivity in Canada has already lowered its realized prices there. US generics are not expected before the early 2030s, but the biopharma patent cliff pattern is familiar: ex-US revenue erodes first, and the terminal value problem moves into today's valuation.

The GLP-1 revolution is generating M&A activity and strategic disruption across every healthcare sub-sector, not just biopharma.

CDMO manufacturing capacity. During the 2022-2025 shortages, manufacturing was the binding constraint, and Novo Nordisk's parent company acquired Catalent for $16.5 billion mainly to secure semaglutide fill-finish capacity. The FDA declared the tirzepatide shortage over in December 2024 and the semaglutide shortage in February 2025, but the deal remains the precedent for how modality-specific capacity constraints can push CDMO valuations to strategic premiums far above standalone analysis. The capacity question now is cost: very high volumes at lower prices.

Healthcare services disruption. GLP-1 adoption threatens established services verticals. Bariatric surgery volumes have declined in markets with high GLP-1 penetration. Sleep apnea device makers (ResMed, Philips) face demand erosion as weight loss eases the condition. Conversely, GLP-1 is creating demand for new services: obesity management clinics, metabolic health monitoring, and cash-pay telehealth platforms.

Medical device adjacency. Cardiovascular device companies face a complex dynamic. If GLP-1 drugs cut cardiovascular events by 20%, long-term demand for stents, pacemakers and heart failure devices could decline, yet patients who live longer may need more procedures over a lifetime. Abbott and Dexcom are positioning continuous glucose monitors as GLP-1 companion diagnostics, creating a new revenue stream.

The GLP-1 market has moved from a supply problem to a price problem, and from two injectable brands to a crowded field of pills, injectables and generics. It will stay the dominant theme in healthcare M&A, but the questions have changed: how fast net prices fall as Medicare, cash channels and generics widen access, whether volume growth outruns them, and which next-generation mechanism the next acquirer pays up for.

The next article covers AI in healthcare, examining how artificial intelligence is moving from conference-deck hype to clinical pipeline reality.